AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ...

AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.